Maze Finds A Way As Shionogi Signs On To Develop Pompe Drug

Months after an antitrust lawsuit challenged its deal with Sanofi and raised uncertainty about the future of MZE001, Maze secured a new partner for potentially the first oral Pompe disease drug.

• Source: Shutterstock

A year after attempting to partner with French drug maker Sanofi – only to have US regulators stop the deal over antitrust concerns – Maze Therapeutics has entered into a similar partnership with Shionogi & Co. Ltd.for the oral Pompe disease drug MZE001.

The companies announced the exclusive worldwide collaboration on 10 May, whereby Shionogi will pay Maze $150m up front, plus undisclosed...

More from Deals

More from Business